Guy's and St Thomas' NHS Foundation Trust at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Guy's and St Thomas' NHS Foundation Trust brings 1 presentation to ASH 2026 in New Orleans. Its program centres on myeloproliferative neoplasms, including essential thrombocythemia and polycythemia vera, and how to handle resistance and disease progression. It also looks at therapies aimed at specific MPN mutations.
| Organization | ASH 2026 Attendance |
|---|---|
Guy's and St Thomas' NHS Foundation Trust London, United Kingdom | |
NHS trust running Guy's and St Thomas' hospitals in London, with a large clinical haematology service. | Symposium Fri Dec 11 3:00pm–6:00pm Cases and Conversations™: Applying Emerging Evidence to Real-World Care in Myeloproliferative Neoplasms Choosing among new myeloproliferative neoplasm drugs, including Janus kinase and telomerase inhibitors, hepcidin mimetics, and calreticulin-targeted antibodies. Symposium Fri Dec 11 11:00am–2:00pm Show Me the Data™: Emerging Evidence and Evolving Clinical Practice in Essential Thrombocythemia and Polycythemia Vera Newer options for polycythemia vera and essential thrombocythemia, such as ropeginterferon and rusfertide, and what to do when hydroxyurea fails. Session Addressing Resistance and Progression in Myeloproliferative Diseases Why myeloproliferative neoplasms persist and progress despite therapy, from clone growth and inflammation to drug resistance, and new mutation-targeted treatments. Talk Mutation-Targeted Therapies in MPN: A New Dawn? Antibodies, vaccines and cell therapies aimed at mutant calreticulin, plus newer Janus kinase inhibitors, for myeloproliferative neoplasms. |
Instantly find 20 buyers from Guy's and St Thomas' NHS Foundation Trust
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction